FinnCap restated their corporate rating on shares of Omega Diagnostics Group Plc (LON:ODX) in a research report sent to investors on Tuesday. FinnCap currently has a GBX 28 ($0.35) price objective on the stock.

Omega Diagnostics Group Plc (LON:ODX) opened at 18.40 on Tuesday. The company’s 50-day moving average is GBX 17.37 and its 200-day moving average is GBX 17.23. Omega Diagnostics Group Plc has a 52 week low of GBX 13.50 and a 52 week high of GBX 21.00. The company’s market cap is GBX 20.01 million.

TRADEMARK VIOLATION WARNING: “Omega Diagnostics Group Plc (ODX) Receives Corporate Rating from FinnCap” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The original version of this piece of content can be viewed at

About Omega Diagnostics Group Plc

Omega Diagnostics Group PLC is a medical diagnostics company. The Company’s segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers.

Receive News & Stock Ratings for Omega Diagnostics Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group Plc and related stocks with our FREE daily email newsletter.